Abramson JS et al. Pivotal safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. ASH 2019;Abstract 241.
Abramson JS et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. ASCO 2018;Abstract 7505.
Bartlett NL et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the Echelon-1 study. ASH 2019;Abstract 4026.
Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018;378(4):331-44. Abstract
Evens AM et al. Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): A detailed analysis from the phase 3 ECHELON-1 study. ASH 2018;Abstract 1618.
Gopal AK et al. PI3δ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract
Greenwell IB et al PI3K inhibitors: Understanding toxicity mechanisms and management. Oncology (Williston Park) 2017;31(11):821-8. Abstract
Horwitz S et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet 2019;393(10168):229-40. Abstract
Kuruvilla J et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). ASCO 2020;Abstract 8005.
Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract
Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract
Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract
Neelapu SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531-44. Abstract
Ramchandren R et al. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res 2019;25(6):1718-26. Abstract
Schuster SJ et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. ASH 2019;Abstact 6.
Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract
Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract
Straus DJ et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. ASCO 2019;Abstract 7532.
Tam CS et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378(13):1211-23. Abstract
van der Stegen SJC et al. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14(7):499-509. Abstract
Varadarajan I, Lee DW. Management of T-cell engaging immunotherapy complications. Cancer J 2019;25(3):223-30. Abstract
Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract